Rybrevant

Confirm presence of EGFR exon 20 insertion mutations in tumor or plasma specimens. Premedicate with antihistamine (oral or IV), antipyretic (oral or IV) prior to all infusions, and glucocorticoid (IV) at initial dose (Week 1 on Days 1 and 2 only), and upon re-initiation after prolonged dose interruptions, then as needed for subsequent infusions. Initiate treatment by IV infusion via peripheral line on Weeks 1 and 2, then may be administered via central line for subsequent weeks. In combination therapy: infuse pemetrexed first, carboplatin second, and amivantamab last; see full labeling. First-line NSCLC: <80kg (Week 1): 350mg on Day 1, then 1050mg on Day 2; (Weeks 2–4): 1400mg once weekly on Day 1; (Weeks 5–6): no dose; (Week 7 onwards): 1750mg every 3 weeks thereafter; ≥80kg (Week 1): 350mg on Day 1, then 1400mg on Day 2; (Weeks 2–4): 1750mg once weekly on Day 1; (Weeks 5–6): no dose; (Week 7 onwards): 2100mg every 3 weeks thereafter. Previously treated NSCLC: <80kg (Week 1): 350mg on Day 1, then 700mg on Day 2; (Weeks 2–5): 1050mg once weekly on Day 1; (Week 6): no dose; (Week 7 onwards): 1050mg every 2 weeks thereafter; ≥80kg (Week 1): 350mg on Day 1, then 1050mg on Day 2; (Weeks 2–5): 1400mg once weekly on Day 1; (Week 6): no dose; (Week 7 onwards): 1400mg every 2 weeks thereafter. Continue until disease progression or unacceptable toxicity. Infusion rates, dose modifications for adverse reactions: see full labeling.